This pilot study evaluates the feasibility and outcomes of two treatment approaches for corneal sensory dysfunction due to neurotrophic keratitis (NK): corneal neurotization surgery and topical Cenergermin (Oxervate). Participants will receive treatment based on clinical decision-making, not randomization, and will be followed for 12 months through eight visits at the Ivey Eye Institute, St. Joseph's Health Care London. Data collected during routine eye examinations and validated quality-of-life questionnaires will be used to assess visual outcomes, corneal structure and function, and patient-reported well-being. This feasibility study is funded by the Lawson Research Institute Internal Research Fund and is intended to generate preliminary evidence for a future randomized trial.
Adults aged 19 years and older.
Diagnosis of neurotrophic keratitis with reduced or absent corneal sensation.
Clinical indication for either corneal neurotization surgery or topical Cenergermin treatment, as determined by the treating ophthalmologist.
Ability to provide informed consent.
Active ocular infection or inflammation.
Previous corneal neurotization procedure in the affected eye.
Contraindications to general anesthesia or surgical intervention.
Participation in another interventional clinical trial within the past 3 months.